READ-ONLY DIGITIZATION RESULT
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Blood · 2025-Jun-05 · PMID 40009494
Panel C提取完成待 EXE 对齐验证
Time from PD to next treatment
Figure 3. Kaplan-Meier estimates by MRD status and MRD conversion among VenR-treated patients in the overall intent-to-treat population. (A) Time to MRD∗ conversion; (B) time from conversion to PD; (C) time from PD to next treatment. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10 –4 ]) and MRD + (≥10 –4 ).
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 1 | 2026-07-23T16:30:11+00:00 |